A Phase 3 clinical trial investigating internal mammary nodal irradiation for high-risk Breast Cancer patients reached its primary completion date on 2025-11-01. The study, which enrolled 2400 participants, aims to assess the impact of this intervention on disease-free survival.
Background
Breast cancer remains a significant global health challenge, with treatment strategies continually evolving to improve patient outcomes. For high-risk patients, particularly those who have undergone mastectomy or breast-conserving surgery, locoregional control is a critical aspect of care. Internal mammary nodal irradiation is a technique used to target lymph nodes located behind the breastbone, which can be a site for cancer recurrence. Evaluating its impact on disease-free survival is crucial for optimizing adjuvant therapy and potentially improving long-term prognoses for these patients.
Trial design
This Phase 3 study, currently active but not recruiting, enrolled 2400 participants with Breast Cancer. The trial's primary objective is to evaluate the impact of internal mammary nodal irradiation on disease-free survival in high-risk breast cancer patients who have been treated with mastectomy or breast-conserving surgery.
What this means
The primary completion of this Phase 3 trial signifies that data collection for the study's main outcome measure is complete. Researchers will now proceed with data analysis to determine the efficacy of internal mammary nodal irradiation in improving disease-free survival for high-risk breast cancer patients. The results are anticipated to provide important evidence that could inform future treatment guidelines and clinical practice for this patient population.
Source
Information regarding this trial's primary completion was obtained from ClinicalTrials.gov, a public database of clinical studies. The entry for study NCT04320979, titled "Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients," was updated on 2025-11-01 on clinicaltrials.gov.